Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparison of Two Chelator Scaffolds as Basis for Cholecystokinin-2 Receptor Targeting Bimodal Imaging Probes

G. Gariglio, K. Bendova, M. Hermann, A. Olafsdottir, JK. Sosabowski, M. Petrik, E. von Guggenberg, C. Decristoforo

. 2024 ; 17 (12) : . [pub] 20241122

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25008828

Grant support
DOI: 10.55776/DOC110 FWF Austrian Science Fund

Background/Objectives: Dual-modality probes, combining positron emission tomography (PET) with fluorescence imaging (FI) capabilities in a single molecule, are of high relevance for the accurate staging and guided resection of tumours. We herein present a pair of candidates targeting the cholecystokinin-2 receptor (CCK2R), namely [68Ga]Ga-CyTMG and [68Ga]Ga-CyFMG. In these probes, the SulfoCy5.5 fluorophore and two units of a CCK2R-binding motif are coupled to the chelator acting as a core scaffold, triazacyclononane-phosphinic acid (TRAP), and Fusarinine C (FSC), respectively. Using this approach, we investigated the influence of these chelators on the final properties. Methods: The synthetic strategy to both precursors was based on the stoichiometric conjugation of the components via click chemistry. The characterization in vitro included the evaluation of the CCK2R affinity and internalization in A431-CCK2R cells. Ex vivo biodistribution as well as PET and FI studies were performed in xenografted mice. Results: 68Ga labelling was accomplished with high radiochemical yield and purity for both precursors. A CCK2R affinity in the subnanomolar range of the conjugates and a receptor-specific uptake of the radioligands in cells were observed. In A431-CCK2R/A431-mock xenografted mice, the investigated compounds showed specific accumulation in the tumours and reduced off-target uptake compared to a previously developed compound. Higher accumulation and prolonged retention in the kidneys were observed for [68Ga]Ga-CyTMG when compared to [68Ga]Ga-CyFMG. Conclusions: Despite the promising targeting properties observed, further probe optimization is required to achieve enhanced imaging contrast at early timepoints. Additionally, the results indicate a distinct influence of the chelators in terms of renal accumulation and retention.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008828
003      
CZ-PrNML
005      
20250422095658.0
007      
ta
008      
250408s2024 sz da f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ph17121569 $2 doi
035    __
$a (PubMed)39770411
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Gariglio, Giacomo $u Department of Nuclear Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria $1 https://orcid.org/0000000251923839
245    10
$a Comparison of Two Chelator Scaffolds as Basis for Cholecystokinin-2 Receptor Targeting Bimodal Imaging Probes / $c G. Gariglio, K. Bendova, M. Hermann, A. Olafsdottir, JK. Sosabowski, M. Petrik, E. von Guggenberg, C. Decristoforo
520    9_
$a Background/Objectives: Dual-modality probes, combining positron emission tomography (PET) with fluorescence imaging (FI) capabilities in a single molecule, are of high relevance for the accurate staging and guided resection of tumours. We herein present a pair of candidates targeting the cholecystokinin-2 receptor (CCK2R), namely [68Ga]Ga-CyTMG and [68Ga]Ga-CyFMG. In these probes, the SulfoCy5.5 fluorophore and two units of a CCK2R-binding motif are coupled to the chelator acting as a core scaffold, triazacyclononane-phosphinic acid (TRAP), and Fusarinine C (FSC), respectively. Using this approach, we investigated the influence of these chelators on the final properties. Methods: The synthetic strategy to both precursors was based on the stoichiometric conjugation of the components via click chemistry. The characterization in vitro included the evaluation of the CCK2R affinity and internalization in A431-CCK2R cells. Ex vivo biodistribution as well as PET and FI studies were performed in xenografted mice. Results: 68Ga labelling was accomplished with high radiochemical yield and purity for both precursors. A CCK2R affinity in the subnanomolar range of the conjugates and a receptor-specific uptake of the radioligands in cells were observed. In A431-CCK2R/A431-mock xenografted mice, the investigated compounds showed specific accumulation in the tumours and reduced off-target uptake compared to a previously developed compound. Higher accumulation and prolonged retention in the kidneys were observed for [68Ga]Ga-CyTMG when compared to [68Ga]Ga-CyFMG. Conclusions: Despite the promising targeting properties observed, further probe optimization is required to achieve enhanced imaging contrast at early timepoints. Additionally, the results indicate a distinct influence of the chelators in terms of renal accumulation and retention.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bendová, Kateřina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, 77900 Olomouc, Czech Republic $7 xx0327299
700    1_
$a Hermann, Martin $u Department of Anesthesiology and Critical Care Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria
700    1_
$a Olafsdottir, Asta $u Perceptive Discovery, Hammersmith Hospital, Imperial College London, London W12 0NN, UK
700    1_
$a Sosabowski, Jane K $u Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London E1 4NS, UK
700    1_
$a Petřík, Miloš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, 77900 Olomouc, Czech Republic $u Czech Advanced Technology and Research Institute, Palacky University, 77900 Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital, 77900 Olomouc, Czech Republic $1 https://orcid.org/0000000313345916 $7 xx0169395
700    1_
$a von Guggenberg, Elisabeth $u Department of Nuclear Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria $1 https://orcid.org/0000000349444705
700    1_
$a Decristoforo, Clemens $u Department of Nuclear Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria $1 https://orcid.org/0000000305664036
773    0_
$w MED00184066 $t Pharmaceuticals $x 1424-8247 $g Roč. 17, č. 12 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39770411 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095700 $b ABA008
999    __
$a ok $b bmc $g 2306498 $s 1245903
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 17 $c 12 $e 20241122 $i 1424-8247 $m Pharmaceuticals $n Pharmaceuticals (Basel) $x MED00184066
GRA    __
$a DOI: 10.55776/DOC110 $p FWF Austrian Science Fund
LZP    __
$b NLK116 $a Pubmed-20250408

Find record

Citation metrics

Archiving options